Deal or No Deal: Corporate and Regulatory Due Diligence Considerations

Posted 01 July 2009 | By

Deals in the pharmaceutical and medical device industries come fast and furiously, frequently with urgent deadlines. Whether the transaction relates to a co-promotion, licensing, contract manufacturing, divesture or acquisition, thorough and focused due diligence is necessary to minimize surprises, which can be very costly. It is also important to recognize that these deals include a critical component not found in a routine commercial transaction in an unregulated industry: the product or company at issue is regulated by the US Food and Drug Administration (FDA) and regulatory issues must be carefully considered.

Categories:

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe